# Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Source: https://onco.cc/trials/nct06043973/  
OnCo record `nct06043973` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of aumolertinib in lung cancer, run by Qianfoshan Hospital, now recruiting.

## Summary

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance is a phase 3, interventional study registered as NCT06043973 by Qianfoshan Hospital, with a registry enrolment figure of 98 participants, started 2023-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: almonertinib. Conditions listed: Advanced Non-small Cell Lung Cancer. Primary outcome: PFS. Lung eligibility wording from the registry: "Metastatic Non-squamous NSCLC is histologically or cytologically proven to be inoperable and cannot receive radical concurrent chemoradiotherapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06043973
- Phase: 3
- Setting: A Prospective Single-center, Single-arm Clinical Study of Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation and TP53 Mutation
- Sponsor: Qianfoshan Hospital
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT06043973: https://clinicaltrials.gov/study/NCT06043973

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06043973.json